VCBeat has learned that Shenzhen Huixin Lifetech Co., Ltd. (hereinafter referred to as “Huixin Lifetech”) has successfully completed its Series A financing, raising nearly RMB 100 million.. This round of financing attracted investments from renowned investors and received strong support from the HAOYUE CAPITAL China Healthcare Industry Fund.HAOYUE CAPITAL served as the exclusive financial advisor for this round of financing and will continue to provide long-term strategic support to Huixin Lifetech. This funding will accelerate Huixin Lifetech’s global business expansion, drive the full automation of upstream separation and purification processes in the exosome and cell industries, while reducing costs, improving efficiency, and enhancing the overall effectiveness of the industry chain. Huixin Lifetech will remain innovation-driven, empowering industry development, leading technological transformation in precision medicine and life sciences, and helping the global health industry reach new heights.

Leveraging its robust technological innovation capabilities, Huixin Lifetech published a cover article in Nature Methods in 2021. Its independently developed EXODUS automated exosome purification platform received high acclaim and was hailed as “the hope for the industrialization of exosomes.” This breakthrough technology rapidly facilitated the company’s angel financing round and accelerated its mass production and commercialization processes. In 2022, the company launched the research-grade EXODUS H300/H600 systems, followed by the official release of the industrial-grade EXODUS-T2800 in May 2024. Equipped with dedicated membrane chip consumables, the system provides efficient GMP-compliant solutions that stably support operations ranging from laboratory process development to medium- and large-scale commercial production. With its superior capacity for processing large-volume samples, the EXODUS-T2800 further drives the efficient, scaled development of the exosome and cell therapy industries, fostering technological innovation in global precision medicine and life sciences.

Within just two years of commercialization, Huixin Lifetech’s EXODUS platform has been installed in over 200 units worldwide, serving top-tier research institutions and industrial clients across the Americas, Asia, and Europe, with broad applications in multiple fields. In the Americas, EXODUS systems have been deployed at prestigious institutions such as Harvard Medical School, the Texas Medical Center, the Nobel Prize-winning laboratory at the University of California, Berkeley, and Capricor, the world’s first publicly listed exosome company. In Asia, users of EXODUS include authoritative academic and medical institutions such as Tsinghua University, the University of Tokyo, Seoul National University, Tongji Hospital, and Peking Union Medical College Hospital. In Europe, EXODUS installations include world-class universities such as the University of Oxford. Downstream users have widely applied the EXODUS platform to diverse research areas, including neurological disorders, oncology, cardiovascular and cerebrovascular diseases, virology and vaccinology, ophthalmology and dentistry, regenerative medicine, and medical aesthetics. Leveraging its leading exosome isolation and purification technology, Huixin Lifetech continues to drive innovative development in precision medicine and life sciences, delivering revolutionary breakthroughs to the global biomedical sector.

Huixin Lifetech’s EXODUS Automated Exosome Purification Platform, leveraging globally independent technological breakthroughs, innovatively integrates negative pressure oscillation with dual-coupled harmonic oscillation to create a highly efficient, standardized, and fully automated separation and purification tool. This technology overturns the inherent limitations of traditional ultracentrifugation or tangential flow filtration methods, such as protein adsorption, restricted nanofiltration flux, and exosome damage, delivering significant advantages including high biological activity, high recovery rates, high purity, excellent batch-to-batch consistency, and full automation. The innovative design of EXODUS substantially enhances the efficiency of exosome isolation and purification, enabling downstream customers to significantly reduce costs, boost productivity, and accelerate the industry’s advancement toward higher standards.

Core Product: The World’s First EXODUS Automated Exosome Purification Instrument Platform

Leveraging the platform-based technological advantages conferred by the EXODUS separation and purification principle, downstream customer validation has demonstrated that, compared to ultracentrifugation, EXODUS delivers higher purity and biological activity in virus isolation, along with a significant increase in yield. Moving forward, Huixin Lifetech will continue to deepen its expertise in the exosome field while actively expanding into the separation and purification of viruses and other microscopic particles of varying sizes. Through continuous innovation and breakthroughs, the company aims to provide leading core productivity tools for global scientific research and industrial clients, thereby supporting the sustained development of the life sciences and biopharmaceutical sectors.

Exosomes (30–150 nm) are extracellular vesicles formed by living cells through processes such as endocytosis, fusion, and exocytosis. They are widely present in various bodily fluids and carry diverse biological information, including proteins, lipids, and nucleic acids associated with their cellular origin. Following isolation and purification, exosomes exhibit excellent targeting capabilities, can exert therapeutic effects comparable to those of stem cells, and feature low immunogenicity, high safety, and strong stability. In 2013, the Nobel Prize in Physiology or Medicine was awarded to scientists who made outstanding contributions to elucidating the regulatory mechanisms of intracellular vesicle transport, sparking a surge of interest in exosome research. A decade later, in 2024, the Nobel Prize in Physiology or Medicine was awarded for discoveries concerning microRNA (miRNA)—closely linked to exosomes—and its role in post-transcriptional gene regulation, further intensifying research enthusiasm in the field of exosomes. The number of exosome-related publications, patents, and funded projects has grown exponentially. Numerous innovative companies worldwide are actively exploring downstream applications of exosomes across multiple sectors, including screening and diagnosis, therapeutics, drug delivery, and medical aesthetics.

Number of Exosome-Related Publications, Patents, and Grants

In May 2022, the National Development and Reform Commission (NDRC) released the "14th Five-Year Plan for Bioeconomy Development," China’s first five-year plan dedicated to the bioeconomy, which explicitly calls for the establishment of a technical platform for quality and safety evaluation of exosome therapeutic products. Driven by both policy support and industrial growth, the exosome industry is poised to enter a golden era of accelerated development. As an upstream "chain leader" enterprise, Huixin Lifetech remains committed to providing efficient core tools to downstream industries, thereby fostering rapid sector-wide advancement. We warmly invite interested investment institutions and business partners to contact us to explore collaboration opportunities and jointly create a promising future.

Upstream separation and purification processes have long been dominated by international companies. In the research sector, ultracentrifuges represented by Beckman Coulter, and in the industrial sector, tangential flow filtration systems represented by Cytiva, hold dominant positions. However, these technologies face challenges in practical applications, such as operational complexity, low recovery rates, and insufficient throughput. In recent years, domestic enterprises have gradually shifted from import substitution to original innovation, achieving significant breakthroughs. Leveraging globally pioneering technical principles, Huixin Lifetech has successfully achieved linear scale-up from research to industrial scenarios, balancing the demands for high purity and high yield. Particle separation at the cellular micro-level holds substantial significance in both research and industrial fields. After separation and purification, exosomes, viruses, microorganisms, nanoparticles, and other entities are expected to be widely applied across multiple industries, including disease diagnosis, drug development, and biomanufacturing.

*Nature Methods* Cover Article: Comparative Analysis of Methodologies Shows EXODUS Delivers High Purity and High Yield

Dr. Liu Fei, Chairman of Huixin Lifetechexpressed heartfelt gratitude to all new and existing shareholders for their trust and support. Huixin Lifetech is positioned at the forefront of a burgeoning emerging sector and cutting-edge technology, with boundless opportunities ahead. Leveraging our global perspective and proprietary original research capabilities, we are committed to delivering revolutionary breakthroughs in the exosome and broader cell therapy industries, thereby reshaping industrial production paradigms. Looking forward, we anticipate collaborating closely with business and capital partners to jointly explore the intricacies of the cellular microcosm, demonstrate the strength of Huixin Lifetech at the global frontier of life science and technology, and drive industrial transformation and technological innovation.

Liu Hao, Founding Partner of Haoyue China Healthcare Industry Fundstated that since 2022, our team has been closely monitoring the development of Huixin Lifetech and its innovative products. In just two years, Huixin Lifetech has achieved remarkable success in its commercialization efforts, with its instruments successfully deployed in top-tier research institutions and renowned pharmaceutical companies both domestically and internationally. This not only highlights the team’s exceptional execution capabilities but also fully demonstrates the superior product competitiveness of the EXODUS system. We believe that, with the support of HAOYUE CAPITAL, Huixin Lifetech will further accelerate its global market expansion, consolidate its leadership position in the field of exosome isolation and purification, and establish EXODUS as a globally recognized industry benchmark, thereby driving industrial transformation and technological innovation.

HAOYUE CAPITAL Managing Director Zhao Jun"We are deeply honored to have assisted Huixin Lifetech in successfully completing this round of financing. Leveraging its industry-leading R&D capabilities, global strategic layout, and exceptional mass production capacity, Huixin Lifetech has achieved remarkable breakthroughs in a short period. We believe that this financing will further drive comprehensive upgrades in Huixin Lifetech’s R&D, production, and market expansion, laying a solid foundation for its future development and accelerating overall progress in the industry. HAOYUE CAPITAL remains firmly confident in Huixin Lifetech’s growth potential and will continue to partner with the company, supporting it in achieving greater success in the global biopharmaceutical sector."

Huixin Lifetech, established in 2017 and headquartered in Shenzhen, has rapidly emerged as a leading provider of core upstream tools for exosome research, leveraging its breakthrough membrane vibration separation technology. The company independently developed EXODUS, the world’s first fully automated system for exosome isolation and purification. This innovative platform employs negative pressure oscillation and ultrasonic oscillation to create a novel membrane vibration separation system. Evaluated by multiple authoritative institutions worldwide, EXODUS demonstrates significantly superior isolation and purification performance compared to traditional methods, successfully overcoming industry technical bottlenecks and greatly accelerating the rapid development of the exosome field. Huixin Lifetech is striving to become a world-class life sciences enterprise, leading exosome technology into a new era.